Targeting RGMb interactions: Discovery and preclinical characterization of potent anti-RGMb antibodies blocking multiple ligand bindings

Targeting RGMb interactions: Discovery and preclinical characterization of potent anti-RGMb antibodies blocking multiple ligand bindings

Therapeutic efficacy with durable responses has been demonstrated with several antibody drugs that block key immune checkpoint receptors, including PD-1, PD-L1, and CTLA-4. Despite the success of these drugs, a substantial proportion of patients do not benefit. Targeting multiple inhibitory pathways...

Full description

Saved in:
Bibliographic Details
Main Authors: Maria Meira, Aurore Frey, Neila Chekkat, Magda Rybczynska, Zaki Sellam, Joon Seok Park, Francesca Smylie Gazzaniga, Alexia Parmentier, Marianne Le Gall, Gordon James Freeman, Dennis Lee Kasper, Arlene Helen Sharpe, Eric Rambeaux, Abdijapar Shamshiev
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Series:mAbs
Subjects:
Cancer immunotherapy
ICI resistance
immune checkpoint
monoclonal antibody
RGMb
Online Access:https://www.tandfonline.com/doi/10.1080/19420862.2024.2432403
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items